Last $1,034 MXN
Change Today -44.84 / -4.16%
Volume 530.0
BAX* On Other Exchanges
Symbol
Exchange
New York
SIX Swiss Ex
Mexico
As of 4:09 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX*) Snapshot

Open
$1,034
Previous Close
$1,079
Day High
$1,034
Day Low
$1,034
52 Week High
12/11/14 - $1,079
52 Week Low
03/18/14 - $890.00
Market Cap
560.5B
Average Volume 10 Days
53.0
EPS TTM
--
Shares Outstanding
542.0M
EX-Date
12/3/14
P/E TM
--
Dividend
$2.01
Dividend Yield
2.65%
Current Stock Chart for BAXTER INTERNATIONAL INC (BAX*)

baxter international inc (BAX*) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX*) Details

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Its BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and certain vaccines. The company’s Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; products and services related to pharmacy compounding, drug formulation, and packaging technologies; and technologies and therapies for peritoneal dialysis, in-center and home hemodialysis, and continuous renal replacement therapy. It sells its products through its direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers to hospitals, kidney dialysis and rehabilitation centers, nursing homes, doctors’ offices, clinical and medical research laboratories, and patients. The company has collaboration with Cell Therapeutics, Inc. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products containing a formulation of omega 3 lipids; Onconova Therapeutics, Inc. for rigosertib, an anti-cancer compound; and Chatham Therapeutics, LLC to develop and commercialize product for the treatments of hemophilia B. It operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. The company was founded in 1931 and is based in Deerfield, Illinois.

61,000 Employees
Last Reported Date: 02/21/14
Founded in 1931

baxter international inc (BAX*) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $687.7K
Corporate Vice President and President of Bio...
Total Annual Compensation: $742.3K
Compensation as of Fiscal Year 2013.

baxter international inc (BAX*) Key Developments

Baxter International Inc. Receives FDA Approval for LSolution for Electrolyte Management During Continuous Renal Replacement Therapy

Baxter International Inc. announced the United States Food and Drug Administration has approved PHOXILLUM Renal Replacement Solutions (BK4/2.5 and B22K4/0) as replacement solutions in continuous renal replacement therapy to correct electrolyte and acid-base imbalances, and in case of drug poisoning when CRRT is used to remove dialyzable substances. The FDA has granted PHOXILLUM orphan drug designation for use in CRRT. Hypophosphatemia (abnormally low concentration of phosphate in the blood) is a common electrolyte disturbance in patients treated with CRRT.1 PHOXILLUM is the only FDA approved pre-mixed solution containing phosphate in a 5L bag. It is designed to facilitate electrolyte management during CRRT by allowing use of a single type of solution across a wide clinical spectrum of acute kidney injury patients. Hemodynamic status and fluid, electrolyte and acid-base balance should be monitored. These abnormalities may be corrected by changing the formulations of replacement solution or by supplementation. The approval includes PHOXILLUM formulations containing different bicarbonate concentrations. CRRT is a dialysis modality used to treat disorders that develop as a result of AKI, especially toxin accumulation, fluid overload, and both acid-base and electrolyte disturbances. Due to its continuous nature, CRRT slowly corrects these abnormalities over time, allowing for treatment to be provided for unstable patients in the intensive care unit. AKI often occurs in hospitalized patients treated in an intensive care environment, and it typically occurs over a few hours to a few days. Patients losing the ability to filter waste products and excess fluid adequately require renal replacement therapy in most cases. Baxter anticipates PHOXILLUM phosphate-containing solutions will be available in the United States in the second quarter of 2015.

Baxter International Inc. Receives FDA Approval for PHOXILLUM Solution for Electrolyte Management During Continuous Renal Replacement Therapy

Baxter International Inc. announced that the United States Food and Drug Administration (FDA) has approved PHOXILLUM Renal Replacement Solutions (BK4/2.5 and B22K4/0) as replacement solutions in continuous renal replacement therapy (CRRT) to correct electrolyte and acid-base imbalances, and in case of drug poisoning when CRRT is used to remove dialyzable substances. The FDA has granted PHOXILLUM orphan drug designation for use in CRRT. Hypophosphatemia (abnormally low concentration of phosphate in the blood) is a common electrolyte disturbance in patients treated with CRRT. 1 PHOXILLUM is the only FDA approved pre-mixed solution containing phosphate in a 5L bag. It is designed to facilitate electrolyte management during CRRT by allowing use of a single type of solution across a wide clinical spectrum of acute kidney injury (AKI) patients.

Baxter Seeks Acquisitions

Baxter International Inc. (NYSE:BAX) will consider acquisitions. Baxter acquired Gambro in 2014 and is making a very good progress in integrating Gambro into Baxter. Bob Hombach, Corporate Vice President and Chief Financial Officer said, "We'd expect both businesses to continue to generate very strong cash flow and that will afford the opportunity to maintain strong balance sheets and investment grade profiles for both companies which will allow each to continue to follow a very disciplined approach to capital allocation which will balance reinvestment in the business with returning value to shareholders through dividends and buyback while maintaining some flexibility to continue to look at augmenting the portfolio through business development activities and bolt-on acquisitions.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX*:MM $1,034.16 MXN -44.84

BAX* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,792 JPY +24.50
Danone SA €60.16 EUR +0.16
Kimberly-Clark Corp $109.85 USD -1.80
Stryker Corp $92.55 USD -0.15
Takeda Pharmaceutical Co Ltd ¥5,738 JPY +111.00
View Industry Companies
 

Industry Analysis

BAX*

Industry Average

Valuation BAX* Industry Range
Price/Earnings 21.4x
Price/Sales 2.3x
Price/Book 4.6x
Price/Cash Flow 20.7x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit www.baxter.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.